Dr. Kim Vanderlinden, CEO & Founder
Our screening test identifies a marker that is present not only in tumors, but precancerous tissue as well, which enables us to identify patients at the earliest stages, and even before the cancer has formed. Early-stage tumors can be small and so our advantage over imaging tests such as mammograms, and CTs etc., is that we do not need tumors to be a certain size. This is much more than a concept, as over 20 clinical trials have been published with over 10,000 patients. The accuracy has been outstanding, with typical sensitivity and specificity rates of 80 to 95%. The screen is safe, inexpensive, easy to conduct in an office with no equipment needed and only takes 15 minutes. Physicians and their patients will have the results before a patient leaves the office. We anticipate that this simple, easy to conduct screen will become a standard component of annual physical exams. Cancer with 600,000 US deaths is 2nd only to heart disease with 650,000 deaths. The test can screen for lung, breast, colon, prostate and uterine cancer, which accounts for approx. 1/2 of all cancer mortality.